- the smoking cessation drug
Chantix, which works on specific parts of the brain, helps people give up smoking in two ways:
-- It provides some satisfaction that nicotine gives, hence lessening withdrawal symptoms
-- It blocks the nicotine from entering relevant parts of the brain, thus eliminating the reward a smoker feels when he/she smokes
Addiction to nicotine is a habit that is very difficult for many smokers to quit. When smokers inhale smoke from a cigarette, nicotine reaches the brain within seconds and binds to nicotinic receptors, which activates the reward pathway in brain circuitry. This stimulates the pleasure center in the brain. The initial effects recede quickly and a cycle of craving and withdrawal takes hold.
Chantix is unique because it is specifically designed to partially activate the nicotinic receptor and reduce the severity of the smoker’s craving and the withdrawal symptoms from nicotine. Moreover, if a person smokes a cigarette while receiving treatment, Chantix has the potential to diminish the sense of satisfaction associated with smoking. This may help to prevent the cycle of nicotine addiction.
Chantix is the fourth new Pfizer medicine to receive FDA approval in 2006.